Show simple item record

dc.contributor.authorSaarenheimo, Jatta
dc.contributor.authorEigeliene, Natalja
dc.contributor.authorAndersen, Heidi
dc.contributor.authorTiirola, Marja
dc.contributor.authorJekunen, Antti
dc.date.accessioned2019-03-25T11:11:18Z
dc.date.available2019-03-25T11:11:18Z
dc.date.issued2019
dc.identifier.citationSaarenheimo, J., Eigeliene, N., Andersen, H., Tiirola, M., & Jekunen, A. (2019). The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i>, <i>9</i>, Article 129. <a href="https://doi.org/10.3389/fonc.2019.00129" target="_blank">https://doi.org/10.3389/fonc.2019.00129</a>
dc.identifier.otherCONVID_28986170
dc.identifier.otherTUTKAID_81046
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/63259
dc.description.abstractTargeted therapies have allowed for an individualized treatment approach in non-small-cell lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy depend on genetic identification of personal tumor profiles. Tissue biopsy is the gold standard for molecular analysis, but non-invasive or minimally invasive liquid biopsy methods are also now used in clinical practice, allowing for later monitoring and optimization of the cancer treatment. The inclusion of liquid biopsy in the management of NSCLC provides strong evidence on early treatment response, which becomes a basis for determining disease progression and the need for changes in treatment. Liquid biopsies can drive the decision making for treatment strategies to achieve better patient outcomes. Cell-free DNA and circulating tumor cells obtained from the blood are promising markers for determining patient status. They may improve cancer treatments, allow for better treatment control, enable early interventions, and change decision making from reactive actions toward more predictive early interventions. This review aimed to present current knowledge on and the usefulness of liquid biopsy studies in NSCLC from the perspective of how it has allowed individualized treatments according to gene profiling and how the method may alter the treatment decisions in the future.fi
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherFrontiers Media SA
dc.relation.ispartofseriesFrontiers in Oncology
dc.rightsCC BY 4.0
dc.subject.otherctDNA
dc.subject.otherNSCLC
dc.subject.otherEGFR
dc.subject.otherpersonalized therapy
dc.subject.othercancer
dc.subject.otherprecision medicine
dc.titleThe Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-201903251933
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.oppiaineNanoscience Centerfi
dc.contributor.oppiaineNanoscience Centeren
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.date.updated2019-03-25T10:15:16Z
dc.description.reviewstatuspeerReviewed
dc.relation.issn2234-943X
dc.relation.numberinseries0
dc.relation.volume9
dc.type.versionpublishedVersion
dc.rights.copyright© 2019 The Authors.
dc.rights.accesslevelopenAccessfi
dc.subject.ysomarkkerit
dc.subject.ysoDNA
dc.subject.ysosyöpäsolut
dc.subject.ysoverenkierto
dc.subject.ysodiagnostiikka
dc.subject.ysobiopsia
dc.subject.ysokeuhkosyöpä
dc.subject.ysosyöpähoidot
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p12288
jyx.subject.urihttp://www.yso.fi/onto/yso/p7690
jyx.subject.urihttp://www.yso.fi/onto/yso/p23898
jyx.subject.urihttp://www.yso.fi/onto/yso/p16243
jyx.subject.urihttp://www.yso.fi/onto/yso/p416
jyx.subject.urihttp://www.yso.fi/onto/yso/p6704
jyx.subject.urihttp://www.yso.fi/onto/yso/p19573
jyx.subject.urihttp://www.yso.fi/onto/yso/p27422
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.3389/fonc.2019.00129


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0